Skip to main content
    S

    SkinHealth Systems Inc. (SKIN)

    Official site

    CONSUMER DEFENSIVE • HOUSEHOLD & PERSONAL PRODUCTS • NASDAQ

    $15.05
    -1.26 (-7.73%)

    Market Cap: $106.26M

    Last updated: Nov 17, 2026 at 11:01 AM ET

    SkinHealth Systems Inc. (SKIN) Earnings: Report Dates and Results

    Updated Nov 5, 2026. Results come from company earnings reports, and estimates are consensus analyst estimates.

    SkinHealth Systems (SKIN) is expected to report earnings on Mar 10, 2027. In the quarter ended Sep 30, 2026, SkinHealth Systems reported EPS of -$0.14, above the -$1.32 estimate. It beat the EPS estimate in 7 of the last 8 quarters.

    Earnings

    Performance (10Y)

    Beat Rate
    71%(17/24)
    Avg Surprise
    +93.09%
    Streak
    3 Q

    Upcoming Estimates

    Reports Mar 10, 2027 (est.)Period ending Dec 31, 2026
    EPS Consensus-$0.47
    Range-$0.96 - -$0.14
    11 analysts
    Revenue Consensus
    $81.25M
    Range$76.34M - $87.36M
    11 analysts
    Reports May 5, 2027 (est.)Period ending Mar 31, 2027
    EPS Consensus-$0.75
    Range-$0.99 - -$0.52
    4 analysts
    EPS Revisions
    1
    2
    30d
    EPS Estimate DriftChange to current
    90d ago-$0.44-71.0%
    60d ago-$0.44-71.0%
    30d ago-$0.44-71.0%
    7d ago-$0.44-72.6%
    Current-$0.75
    Revenue Consensus
    $65.10M
    Range$62.90M - $68.10M
    5 analysts

    Next Report

    SKIN has an expected report date of Mar 10, 2027.

    SKIN Earnings Call

    The latest SKIN earnings call transcript on file is labeled 2026Q3.

    Read the 2026Q3 transcript

    Earnings History

    Of the 24 quarters below that had an estimate, SKIN beat 17, missed 6 and matched 1. Revenue for the quarter ended Sep 30, 2026 was $69.17M, down 2.1% from $70.66M a year earlier.

    Quarter endedEPSEstimateRangeSurpriseResultYoYAnalystsRevisionsReportedRevenue
    Sep 30, 2026-$0.14-$1.32N/A+89.39%Beat-566.7%10 up, 0 downNov 5, 2026$69.17M
    Jun 30, 2026-$0.02-$0.04-$0.06 - -$0.01+50.00%Beat-166.7%74 up, 0 downAug 6, 2026$72.11M
    Mar 31, 2026$0.03-$0.01N/A+400.00%Beat-25.0%71 up, 4 downMay 7, 2026$64.91M
    Dec 31, 2025-$0.06-$0.04-$0.08 - -$0.02-58.73%MissN/A61 up, 1 downMar 12, 2026$82.37M
    Sep 30, 2025$0.03-$0.05-$0.06 - -$0.04+160.00%Beat-25.0%20 up, 0 downNov 6, 2025$70.66M
    Jun 30, 2025$0.03-$0.06N/A+150.00%Beat-62.5%10 up, 0 downAug 7, 2025$78.19M
    Mar 31, 2025$0.04-$0.07-$0.07 - -$0.07+157.14%Beat-20.0%10 up, 0 downMay 8, 2025$69.58M
    Dec 31, 2024-$0.08-$0.10-$0.13 - -$0.05+20.00%Beat-900.0%20 up, 0 downMar 12, 2025$83.50M
    Sep 30, 2024$0.04-$0.04N/A+200.00%Beat-20.0%60 up, 0 downNov 12, 2024$78.80M
    Jun 30, 2024$0.08$0.01-$0.11 - $0.02+700.00%Beat-46.7%92 up, 0 downAug 8, 2024$90.59M
    Mar 31, 2024$0.05-$0.07N/A+171.43%BeatN/A90 up, 0 downMay 9, 2024$81.40M
    Dec 31, 2023$0.01-$0.07-$0.12 - $0.00+114.29%Beat-80.0%80 up, 0 downMar 12, 2024$96.82M
    Sep 30, 2023$0.05$0.09$0.07 - $0.11-44.44%Miss0.0%81 up, 0 downNov 13, 2023$97.41M
    Jun 30, 2023$0.15$0.05$0.03 - $0.11+200.00%Beat+1400.0%80 up, 0 downAug 9, 2023$117.48M
    Mar 31, 2023-$0.04-$0.02-$0.07 - $0.02-100.00%MissN/A90 up, 1 downMay 10, 2023$86.28M
    Dec 31, 2022$0.05$0.04$0.00 - $0.07+25.00%Beat+400.0%80 up, 0 downFeb 28, 2023$98.13M
    Sep 30, 2022$0.05$0.02-$0.03 - $0.05+150.00%Beat+150.0%90 up, 0 downNov 8, 2022$88.79M
    Jun 30, 2022$0.01$0.02N/A-50.00%Miss-88.9%N/A0 up, 1 downAug 9, 2022$103.54M
    Mar 31, 2022-$0.06$0.01-$0.03 - $0.01-700.00%MissN/A90 up, 0 downMay 10, 2022$75.42M
    Dec 31, 2021$0.01-$0.02-$0.04 - $0.00+150.00%BeatN/A8N/AFeb 22, 2022$77.89M
    Sep 30, 2021$0.02-$0.01-$0.03 - $0.01+300.00%BeatN/A62 up, 1 downNov 9, 2021$68.15M
    Jun 30, 2021$0.09$0.02-$0.02 - $0.02+350.00%BeatN/A6N/AJul 1, 2021$66.51M
    Mar 31, 2021-$0.06-$0.02N/A-200.00%MissN/AN/AN/AMay 13, 2021$47.54M
    Dec 31, 2020-$0.02-$0.02N/A0.00%In lineN/AN/AN/AMar 18, 2021$37.88M
    Sep 30, 2020-$135.60N/AN/AN/AN/A-362.2%N/AN/ANov 16, 2020$34.56M
    Sep 30, 2019$51.72N/AN/AN/AN/AN/AN/AN/ADec 31, 2019N/A
    Last 26 quarters

    Annual EPS

    EPS for the fiscal year ended Dec 31, 2025 was $0.04, down 55.6% from the year before. It was -$83.90 for the year ended Dec 31, 2020, the oldest of the 6 fiscal years shown.

    Fiscal year endedEPSChange
    Dec 31, 2025$0.04-55.6%
    Dec 31, 2024$0.09-47.1%
    Dec 31, 2023$0.17+240.0%
    Dec 31, 2022$0.05N/A
    Dec 31, 2021$0.06N/A
    Dec 31, 2020-$83.90N/A

    Earnings Calls

    The 8 most recent earnings calls are listed below; the latest, 2026Q3 for the period ended Sep 30, 2026, runs about 5,400 words across 10 speakers.

    CallPeriod endingWordsSpeakersTranscript
    2026Q3Sep 30, 20265,38610
    2026Q2Jun 30, 20265,27911
    2026Q1Mar 31, 20265,37711
    2025Q4Dec 31, 20255,8178
    2025Q3Sep 30, 20255,02510
    2025Q2Jun 30, 20255,45412
    2025Q1Mar 31, 20255,04310
    2024Q4Dec 31, 20246,60411

    2026Q3 Earnings Call

    Opening remarks

    Norberto Aja Investor Relations Thank you, operator, and good afternoon, everyone. Thank you for joining SkinHealth Systems' third quarter 2026 conference call. We released our results earlier this afternoon, which can be found on our corporate website at skinhealthsystems.com. Joining me on the call today is SkinHealth Systems President and Chief Executive Officer, Pedro Malha, along with our Chief Financial Officer, Mike Monahan. Before we begin, I want to remind everyone of the company's safe harbor language. Management may make forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, including guidance and underlying assumptions. Forward-looking statements are based on current expectations and beliefs and involve risks and uncertainties that could cause actual results to differ materially. Listeners are cautioned not to place undue reliance on any forward-looking statements. For a further discussion of risks related to our business, please refer to the risk factors contained in the company's filings with the Securities and Exchange Commission. In addition, this call will present non-GAAP financial measures. Management uses adjusted EBITDA and other non-GAAP measures as supplemental measures to evaluate operating performance and to facilitate period-to-period comparisons. These non-GAAP measures should be considered in addition to, and not as a substitute for, financial information prepared in accordance with GAAP. A reconciliation of these non-GAAP financial measures to the most comparable GAAP measure is available in the earnings press release, which was furnished to the SEC, as well as available on our website. Following management's prepared remarks, we will open the call for a question-and-answer session. With that, I would now like to turn the call over to our President and CEO, Pedro Malha. Please go ahead, Pedro.

    Pedro Malha President and CEO Thank you, Norberto, and good afternoon, everybody. Let me start with a central message from this quarter. We are making progress on the things that matter the most: stabilizing the Hydrafacial business and improving the economics of the company. At the same time, we are developing new opportunities for growth. To be clear, the work isn't done. Equipment sales remain challenging, particularly in EMEA, and utilization in our installed base is still below where it should be. But we are making good progress against our plan, and the third quarter results provide tangible evidence that we are operating from a stronger foundation than a year ago. Our third quarter revenue was $69.2 million, toward the upper end of our $65 million-$70 million guidance range, meaning that our quarterly revenue declined 2.1% year-over-year, which is a meaningful improvement from the declines of 7.8% in the second quarter and 6.7% in the first quarter.

    Frequently Asked Questions About SKIN

    When is SkinHealth Systems's next earnings date?

    SkinHealth Systems's next earnings report is expected for Mar 10, 2027.

    Did SKIN beat earnings estimates last quarter?

    Yes. SkinHealth Systems reported EPS of -$0.14 for the quarter ended Sep 30, 2026, above the -$1.32 estimate, a 89.39% surprise.

    What EPS do analysts expect from SKIN next quarter?

    The consensus EPS estimate for SkinHealth Systems for the quarter ending Dec 31, 2026 is -$0.47 from 11 analysts, with estimates from -$0.96 to -$0.14.

    How often does SKIN beat earnings estimates?

    SkinHealth Systems beat the EPS estimate in 7 of the last 8 quarters, with an average surprise of +120.98%.